- Home
- ACET vs FBRX Comparison
ACET vs FBRX Comparison
Compare ACET & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- FBRX
- Stock Information
- Founded
- ACET 1947
- FBRX N/A
- Country
- ACET United States
- FBRX United States
- Employees
- ACET N/A
- FBRX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- FBRX Health Care
- Exchange
- ACET Nasdaq
- FBRX Nasdaq
- Market Cap
- ACET 55.1M
- FBRX 44.8M
- IPO Year
- ACET N/A
- FBRX N/A
- Fundamental
- Price
- ACET $0.75
- FBRX $8.83
- Analyst Decision
- ACET Buy
- FBRX Strong Buy
- Analyst Count
- ACET 6
- FBRX 3
- Target Price
- ACET $6.00
- FBRX $80.50
- AVG Volume (30 Days)
- ACET 768.4K
- FBRX 65.6K
- Earning Date
- ACET 05-06-2025
- FBRX 05-15-2025
- Dividend Yield
- ACET N/A
- FBRX N/A
- EPS Growth
- ACET N/A
- FBRX N/A
- EPS
- ACET N/A
- FBRX N/A
- Revenue
- ACET N/A
- FBRX N/A
- Revenue This Year
- ACET N/A
- FBRX N/A
- Revenue Next Year
- ACET N/A
- FBRX N/A
- P/E Ratio
- ACET N/A
- FBRX N/A
- Revenue Growth
- ACET N/A
- FBRX N/A
- 52 Week Low
- ACET $0.45
- FBRX $4.11
- 52 Week High
- ACET $1.70
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- ACET 56.33
- FBRX 55.94
- Support Level
- ACET $0.64
- FBRX $8.25
- Resistance Level
- ACET $0.72
- FBRX $13.84
- Average True Range (ATR)
- ACET 0.06
- FBRX 1.37
- MACD
- ACET 0.01
- FBRX 0.14
- Stochastic Oscillator
- ACET 74.37
- FBRX 33.11
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).